DarioHealth (NASDAQ:DRIO) Downgraded to Sell Rating by Wall Street Zen

DarioHealth (NASDAQ:DRIO) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Sunday.

A number of other research analysts have also recently issued reports on the stock. Stifel Nicolaus set a $16.00 price target on shares of DarioHealth in a report on Friday, November 14th. TD Cowen reiterated a “hold” rating on shares of DarioHealth in a research note on Friday, November 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DarioHealth in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $32.00.

DarioHealth Trading Down 0.8%

Shares of NASDAQ:DRIO opened at $11.64 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.55 and a quick ratio of 4.02. The firm has a market capitalization of $78.69 million, a P/E ratio of -1.04 and a beta of 1.05. The business’s 50-day moving average is $11.99 and its 200 day moving average is $12.00. DarioHealth has a 1 year low of $5.93 and a 1 year high of $17.74.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DarioHealth stock. XTX Topco Ltd increased its holdings in shares of DarioHealth Corp. (NASDAQ:DRIO) by 229.0% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 62,511 shares of the company’s stock after acquiring an additional 43,513 shares during the period. XTX Topco Ltd owned approximately 0.14% of DarioHealth worth $42,000 as of its most recent SEC filing. 33.39% of the stock is currently owned by hedge funds and other institutional investors.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.